Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection

Vinay Sundaram,1 Kris V Kowdley21Department of Medicine and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, 2Liver Care Network, Swedish Medical Center, Seattle, WA, USAAbstract: Chronic hepatitis C virus (HCV) infection is one of the most common etiologies of liver-re...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sundaram V, Kowdley KV
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	pegylated interferon ribavirin genotype 1 direct acting antiviral Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/ba5f8beb2510482eb17737c373e19364
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ba5f8beb2510482eb17737c373e19364
record_format	dspace
spelling	oai:doaj.org-article:ba5f8beb2510482eb17737c373e193642021-12-02T00:51:38ZRole of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection1179-1535https://doaj.org/article/ba5f8beb2510482eb17737c373e193642016-06-01T00:00:00Zhttps://www.dovepress.com/role-of-ledipasvirsofosbuvir-combination-for-genotype-1-hepatitis-c-vi-peer-reviewed-article-HMERhttps://doaj.org/toc/1179-1535Vinay Sundaram,1 Kris V Kowdley21Department of Medicine and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, 2Liver Care Network, Swedish Medical Center, Seattle, WA, USAAbstract: Chronic hepatitis C virus (HCV) infection is one of the most common etiologies of liver-related mortality throughout the world. Among the six HCV genotypes, genotype 1 was significantly more aggressive when utilizing the combination of pegylated interferon and ribavirin, as genotype 1-infected patients had the lowest likelihood of achieving cure (40%–50%) and required twice as long duration of treatment, as compared to genotypes 2 and 3. Recently, however, significant advances have been made with the advent of all-oral direct-acting antiviral agents, which have significantly improved the safety, efficacy, and tolerability of the treatment of HCV genotype 1. Among the available treatments for HCV genotype 1, the combination therapy of ledipasvir/sofosbuvir provides several advantages compared to other regimens, including use of a single-pill regimen, possibility to shorten the duration of treatment to 8 weeks, efficacy in patients exposed to protease inhibitors, safety in decompensated cirrhosis, and potential to avoid ribavirin. In this review, we discuss the pharmacotherapy of the combination of ledipasvir/sofosbuvir therapy and summarize the results of the Phase III clinical trials for this treatment in HCV genotype 1 patients. We will also discuss the data for special populations, including decompensated cirrhosis, human immunodeficiency virus (HIV) coinfected patients, African-Americans, the elderly, and those who failed sofosbuvir-containing regimens.Keywords: pegylated interferon, ribavirin, cirrhosis, liver transplantation, direct-acting antiviralSundaram VKowdley KVDove Medical Pressarticlepegylated interferonribaviringenotype 1direct acting antiviralDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol 2016, Iss Issue 1, Pp 75-80 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	pegylated interferon ribavirin genotype 1 direct acting antiviral Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	pegylated interferon ribavirin genotype 1 direct acting antiviral Diseases of the digestive system. Gastroenterology RC799-869 Sundaram V Kowdley KV Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
description	Vinay Sundaram,1 Kris V Kowdley21Department of Medicine and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, 2Liver Care Network, Swedish Medical Center, Seattle, WA, USAAbstract: Chronic hepatitis C virus (HCV) infection is one of the most common etiologies of liver-related mortality throughout the world. Among the six HCV genotypes, genotype 1 was significantly more aggressive when utilizing the combination of pegylated interferon and ribavirin, as genotype 1-infected patients had the lowest likelihood of achieving cure (40%–50%) and required twice as long duration of treatment, as compared to genotypes 2 and 3. Recently, however, significant advances have been made with the advent of all-oral direct-acting antiviral agents, which have significantly improved the safety, efficacy, and tolerability of the treatment of HCV genotype 1. Among the available treatments for HCV genotype 1, the combination therapy of ledipasvir/sofosbuvir provides several advantages compared to other regimens, including use of a single-pill regimen, possibility to shorten the duration of treatment to 8 weeks, efficacy in patients exposed to protease inhibitors, safety in decompensated cirrhosis, and potential to avoid ribavirin. In this review, we discuss the pharmacotherapy of the combination of ledipasvir/sofosbuvir therapy and summarize the results of the Phase III clinical trials for this treatment in HCV genotype 1 patients. We will also discuss the data for special populations, including decompensated cirrhosis, human immunodeficiency virus (HIV) coinfected patients, African-Americans, the elderly, and those who failed sofosbuvir-containing regimens.Keywords: pegylated interferon, ribavirin, cirrhosis, liver transplantation, direct-acting antiviral
format	article
author	Sundaram V Kowdley KV
author_facet	Sundaram V Kowdley KV
author_sort	Sundaram V
title	Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
title_short	Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
title_full	Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
title_fullStr	Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
title_full_unstemmed	Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
title_sort	role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis c virus infection
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/ba5f8beb2510482eb17737c373e19364
work_keys_str_mv	AT sundaramv roleofledipasvirsofosbuvircombinationforgenotype1hepatitiscvirusinfection AT kowdleykv roleofledipasvirsofosbuvircombinationforgenotype1hepatitiscvirusinfection
_version_	1718403462621822976

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection

Ejemplares similares